{"transactions":[{"id":920754,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"officer":true,"officer_title":"Chief Legal Ofc. and Corp Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T16:12:56.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":195000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000929638-26-000483","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796465/000092963826000483/form4.xml","form_type":"4"}},{"id":1289091,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"officer":true,"officer_title":"Chief Legal Ofc. and Corp Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T16:42:31.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":250000,"derivative":{"exercise_price":7.39,"expiration_date":"2035-01-29","underlying":"Common Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000929638-25-000479","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796465/000092963825000479/form4.xml","form_type":"4"}},{"id":1566966,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"officer":true,"officer_title":"Chief Legal Ofc. and Corp Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-19T16:05:31.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 25% on January 29, 2025, which is the first anniversary of Mr. Giguere's employment commencement date, with the remaining portion to vest monthly over the remaining three years."}],"balance_after":225000,"derivative":{"exercise_price":16.85,"expiration_date":"2034-03-15","underlying":"Common Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000929638-24-001049","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796465/000092963824001049/form4.xml","form_type":"4"}},{"id":2612714,"issuer":{"id":136487,"kind":"organization","name":"CHIASMA, INC","symbol":"CHMA"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-05T17:34:58.000Z","date":"2021-08-05","kind":"disposition_to_issuer","acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of\nMay 4, 2021, by and among Chiasma, Inc. (the \"Company), Amryt Pharma plc (\"Parent\"), and Acorn Merger Sub, Inc., an indirect wholly-owned\nsubsidiary of Parent (\"Merger Sub\") pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving\nas an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":4.55,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-21-050023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1339469/000120919121050023/doc4.xml","form_type":"4"}},{"id":2612713,"issuer":{"id":136487,"kind":"organization","name":"CHIASMA, INC","symbol":"CHMA"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-05T17:34:58.000Z","date":"2021-08-05","kind":"disposition_to_issuer","acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of\nMay 4, 2021, by and among Chiasma, Inc. (the \"Company), Amryt Pharma plc (\"Parent\"), and Acorn Merger Sub, Inc., an indirect wholly-owned\nsubsidiary of Parent (\"Merger Sub\") pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving\nas an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":4.57,"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-21-050023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1339469/000120919121050023/doc4.xml","form_type":"4"}},{"id":2612712,"issuer":{"id":136487,"kind":"organization","name":"CHIASMA, INC","symbol":"CHMA"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-05T17:34:58.000Z","date":"2021-08-05","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of\nMay 4, 2021, by and among Chiasma, Inc. (the \"Company), Amryt Pharma plc (\"Parent\"), and Acorn Merger Sub, Inc., an indirect wholly-owned\nsubsidiary of Parent (\"Merger Sub\") pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving\nas an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to\nthe Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed\nby Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the\nnumber of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down,\nif necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS\n(rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by\n(b) the Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":4.68,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-050023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339469/000120919121050023/doc4.xml","form_type":"4"}},{"id":2866137,"issuer":{"id":136487,"kind":"organization","name":"CHIASMA, INC","symbol":"CHMA"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-11T17:36:42.000Z","date":"2021-02-09","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Common Stock underlying the option will vest in quarterly installments over 4 years from the date of grant, provided continued employment with the Company on each such vesting date."}],"balance_after":90000,"derivative":{"exercise_price":4.55,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-21-009810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339469/000120919121009810/doc4.xml","form_type":"4"}},{"id":3266282,"issuer":{"id":136487,"kind":"organization","name":"CHIASMA, INC","symbol":"CHMA"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-18T16:05:39.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Common Stock underlying the option will vest in quarterly installments over 4 years from the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":4.57,"expiration_date":"2030-02-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-20-010042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339469/000120919120010042/doc4.xml","form_type":"4"}}]}